Skip to main content
OpenTrials
Completed

NCT Number: NCT04689438

GCF Levels of IL-1β and IL-6 in Gingivitis and Stage III-Grade C Periodontitis

Periodontal diseases are chronic diseases that occur as a result of a violation of the balance between microbial dental plaque and the host response. Gingivitis is a disease characterized by inflammation of the gingiva that occurs in one or more areas without loss of attachments.1 in periodontitis, an inflammatory event that begins in the gingiva along with gingivitis spreads to the periodontal ligament, alveolar bone and soft tissues that support the tooth, causing the destruction of these structures.2 Cytokines are low molecular weight proteins that participate in the initial and active stages of inflammation and immunity. In periodontal disease pathogenesis, cytokine response has been reported to play a very critical role in determining disease progression.3 IL-1beta and IL-6 are key cytokines in chronic inflammatory diseases and have the potential to initiate bone loss and tissue destruction seen in periodontal disease.4the purpose of this study; it is to determine the degree of inflammation and periodontal destruction by determining the levels of IL-1beta and IL-6 cytokines in the gingival crevicular fluid of periodontal healthy and diseased individuals.

Completed

Looking for future studies?

Notify Me

Key information

Age range

20 year–65 year

Sex eligibility

All sexes

Study type

Observational

Primary location

University of Usak

Uşak, 64200, Turkey (Türkiye)

About this study

Periodontal measurement were done at 6 sites per tooth After clinical evaluation, individuals were divided into 3 groups

  • Healthy control groups:

clinically healthy gingiva

  • Gingivitis groups:

BOP score of 10% or greater and PD≤3mm

  • Periodontitis groups:

AL ≥5 mm, PD≥6 mm and tooth loss due to periodontitis of ≤4. GCF samples were collected using strips.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • have periodontitis
  • have 16 permanent teeth

Exclusion criteria

  • Systemic disease
  • using drugs

Treatment and study plan

gingival crevicular fluid

Diagnostic Test

GCF samples were collected in the morning hours 24-48 hours after clinical periodontal measurement.

Primary outcomes

  1. Measurement of IL-1Beta level

    Time frame: GCF was taken within 1 week after clinical examination

    GCF was taken interproximal region.

  2. Measurement of IL-6 level in GCF

    Time frame: GCF was taken within 1 week after clinical examination

    GCF was taken interproximal region.

Sponsors and collaborators

Lead sponsor

Uşak University

Other

Registry information

Official study title

Usak University Faculty of Dentistry

Important dates

Study start
2020
Primary completion
2020
Study completion
2020
First posted
Dec 30, 2020
Registry last updated
Nov 4, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.